Haemonetics (NYSE:HAE) Releases FY25 Earnings Guidance

Haemonetics (NYSE:HAE - Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of $4.45-$4.75 for the period, compared to the consensus EPS estimate of $4.40. The company issued revenue guidance of $1.37-$1.41 billion, compared to the consensus revenue estimate of $1.37 billion. Haemonetics also updated its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Stock Performance

Shares of NYSE HAE traded down $0.66 during midday trading on Thursday, reaching $92.59. 887,636 shares of the company were exchanged, compared to its average volume of 463,718. The stock has a market cap of $4.70 billion, a P/E ratio of 37.64, a PEG ratio of 2.23 and a beta of 0.34. Haemonetics has a 1 year low of $70.74 and a 1 year high of $97.13. The stock has a fifty day simple moving average of $83.98 and a 200 day simple moving average of $82.88. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.10. The company had revenue of $336.20 million for the quarter, compared to analysts' expectations of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. Haemonetics's revenue was up 10.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.85 EPS. On average, research analysts forecast that Haemonetics will post 3.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HAE shares. Barrington Research reissued an outperform rating and set a $105.00 target price on shares of Haemonetics in a research note on Friday, April 12th. StockNews.com downgraded Haemonetics from a buy rating to a hold rating in a report on Friday, March 22nd. Finally, TheStreet downgraded shares of Haemonetics from a b- rating to a c+ rating in a report on Thursday, February 29th.

Insider Activity at Haemonetics

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the firm's stock in a transaction on Monday, May 6th. The stock was sold at an average price of $95.00, for a total transaction of $218,975.00. Following the completion of the transaction, the executive vice president now owns 12,295 shares of the company's stock, valued at $1,168,025. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.79% of the stock is owned by corporate insiders.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.